Journal of Infection and Chemotherapy

, Volume 2, Issue 1, pp 40–45 | Cite as

Combination antibiotic/rhG-CSF therapy for bacterially infected granulocytopenic patients

  • Keisuke Toyama
  • Makoto Yaguchi
  • Nobuyoshi Tsuruoka
  • Ken-ichiro Hino
  • Masanori Umeda
  • Ken Shikoshi
  • Yasuo Ikeda
  • Takuro Shinbo
  • Masao Kikuchi
  • Nobuo Aoki
  • Shinsaku Hirosawa
  • Kiyoshi Izawa
  • Isao Aoki
Original Articles
  • 6 Downloads

Abstract

A clinical efficacy rate of 80.8% was obtained in 26 severely infected patients, neutropenic as a result of hematologic disease, following three-drug combination therapy with sulbactam/cefoperazone (SBT/CPZ), piperacillin (PIPC), and human recombinant granulocyte colony stimulating factor (rhG-CSF). By day 4 of treatment, patients average body temperature decreased from 38.6±0.8°C to 37.1±0.7°C and their neutrophil counts increased from 298±347/μL to 1757±2239/μL. When compared with 31 similar patients previously treated with SBT/CPZ and PIPC but without rhG-CSF, the efficacy rate in this study was somewhat higher but the difference was not statistically significant. However, there were statistically significant differences in body temperature on day 4 (37.1±0.7°C vs. 37.8±1.0°C) and in duration of fever in responding cases (3.1±1.7 vs. 4.8±2.4 days). These results suggest that addition of rhG-CSF provides a more rapid response and that the three-drug combination therapy can be selected as empiric therapy for infections in neutropenic patients.

Key words

Sulbactam/cefoperazone piperacillin rhG-CSF neutropenia pneumonia sepsis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bodey GP. Infection in cancer patients. A continuing association. Am J Med 1986;81 (1A):11–26.PubMedGoogle Scholar
  2. 2.
    Pizzo PA, Robichaud KJ, Gill GA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101–111.CrossRefPubMedGoogle Scholar
  3. 3.
    Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the use of anti microbial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381–396.PubMedGoogle Scholar
  4. 4.
    Rintala E. Incidence and clinical significance of positive blood cultures in fibril episodes of patients with hematological malignancies. Scand J Infect Dis 1994;26:77–84.PubMedGoogle Scholar
  5. 5.
    Toyama K, Torii Y, Aoki I, Kikuchi M, Wakasugi K. Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders. Jpn J Antibiot 1992;45:1003–1008.PubMedGoogle Scholar
  6. 6.
    Valdivieso M. Bacterial infection in hematological disease. Clin Hematol 1976;5:229–248.Google Scholar
  7. 7.
    Minami S, Matsubara N, Muraoka T, Kurashige T, Mitsuhashi S. In vitro and in vivo antibacterial activity of cefoperazone (T-1551). Chemotherapy 1980;28(suppl 6):S1-S13.Google Scholar
  8. 8.
    Deguchi K, Yokota N, Koguchi M, Suzuki Y, Suzuki K, Fukuyama S, et al. Antimicrobial activities of major oral antibacterial agents against clinically isolated microbial strains from inpatients. Jpn J Antibiot 1992;45:965–979.PubMedGoogle Scholar
  9. 9.
    Nishino T, Nakazawa T, Otsuki M, Tanino T. In vitro antibacterial activity sulbactam in combination with cefoperazone. Chemothersapy 1984;32(suppl 4):S51-S65.Google Scholar
  10. 10.
    Yokota T. Current status of beta-lactamase production by clinical isolates: studies in 432 hospital. Chemotherapy 1991;39:941–952.Google Scholar
  11. 11.
    Komoto A, Ogawa M, Sugi H, Nakamori Y. Combined effect of sulbactam/cefoperazone (SBT/CPZ) and piperacillin (PIPC) againstP. aeruginosa. The 28th Meeting of the JapanPseudomonas aeruginosa Society, 1994:179–184.Google Scholar
  12. 12.
    Kitamura K, Takaku F, Miyazaki T, Miura A, Mizoguchi H, Saito H, et al. Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders. Jpn J Antibiot 1991;44:979–986.PubMedGoogle Scholar
  13. 13.
    Urabe A, Takaku F, Mizoguchi H, Miura Y, Aoki N, Nomura T, et al. Clinical efficacy of imipenem/cilastatin sodium (IPM/CS) on various infections accompanying in hematological disorders. Antibiot Chemother 1990;6:1989–1998.Google Scholar
  14. 14.
    Urabe A, Takaku F, Mizoguchi H, Teramura M, Naruse T, Karasawa F, et al. Usefulness of ceftazidime (CAZ) for severe infection associated with hematological diseases. Antibiot Chemother 1989;5:1548–1554.Google Scholar
  15. 15.
    Toyama K, Yaguchi M, Wakasugi K, Ogawa T, Oshima T, Tsuruoka N, et al. Clinical evaluation of combination therapy with tobramycin and ceftazidime for severe infections associated with hematological disorders. Chemotherapy 1993;41:911–919.Google Scholar
  16. 16.
    Ieki, R, Kudoh S, Kimura H, Ogawa K, Asano S, Takaku F. Human granulocyte colony formation in serum-free culture stimulated with purified recombinant granulocyte colony-stimulating factor. Exp Hematol 1990;18:883–887.PubMedGoogle Scholar
  17. 17.
    Itoh Y, Kuratsuji T, Tsunawaki S, Aizawa S, Toyama K. In vivo effects of recombinant human granulocyte colony-stimulating factor on normal neutrophil function and membrane effector molecule expression. Int J Hematol 1991;54:463–469.PubMedGoogle Scholar
  18. 18.
    Sheridan WP, Morstyn G, Wolf M, Dodds A, Lusk J, Maher D, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone-marrow transplantation. Lancet 1989;ii:891–895.Google Scholar
  19. 19.
    Kojima S, Fukuda M, Miyajima Y, Matsuyama T, Horibe K. Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor. Blood 1991;77:937–941.PubMedGoogle Scholar
  20. 20.
    Negrin RS, Naeuber DH, Nagler A, Olds LC, Donlon T, Souza LM, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a phase I–II trial. Ann Intern Med 1989;110:976–984.PubMedGoogle Scholar
  21. 21.
    Adachi N, Hashiyama M, Matsuda I. rhG-CSF and aztreonam as prophylaxis against infection in neutropenic children. Lancet 1991;337:1174.CrossRefPubMedGoogle Scholar
  22. 22.
    Matsumoto M, Matsubara S, Matsuno T, Ono M, Yokota T. Protective effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) against various microbial infection in neutropenic mice. Microbiol Immunol 1990;34:765–773.PubMedGoogle Scholar
  23. 23.
    Funada H, Machi T, Ohtake S, Yoshida T, Matsuda T. Effect of recombinant human granulocyte colony-stimulating factor (G-CSF) in the treatment ofPseudomonas aeruginosa bacteremia complicating hematologic malignancy — a preliminary study. J Jpn Infect Dis 1992;66:76–80.Google Scholar
  24. 24.
    Yaguchi M, Toyama K, Ikeda Y, Aoki I, Watanabe K, Kawato M, et al. Effectiveness of concomitant therapy with amikacin, imipenem/cilastatin and human recombinant granulocyte colony stimulating factor for infected neutropenic patients with hematologic diseases. Jpn J Clin Hematol 1994;35:1079.Google Scholar

Copyright information

© Japan Society of Chemotherapy 1996

Authors and Affiliations

  • Keisuke Toyama
    • 9
  • Makoto Yaguchi
    • 9
  • Nobuyoshi Tsuruoka
    • 1
  • Ken-ichiro Hino
    • 1
  • Masanori Umeda
    • 2
  • Ken Shikoshi
    • 2
  • Yasuo Ikeda
    • 3
  • Takuro Shinbo
    • 4
  • Masao Kikuchi
    • 5
  • Nobuo Aoki
    • 6
  • Shinsaku Hirosawa
    • 6
  • Kiyoshi Izawa
    • 7
  • Isao Aoki
    • 8
  1. 1.Department of HematologyShowa University School of MedicineTokyoJapan
  2. 2.First Department of Internal MedicineToho University School of MedicineTokyoJapan
  3. 3.Department of Internal Medicine, School of MedicineKeio UniversityTokyoJapan
  4. 4.Department of Internal MedicineThe Second Tokyo National HospitalTokyoJapan
  5. 5.Department of Internal MedicineTachikawa Mutual HospitalTokyoJapan
  6. 6.First Department of Internal MedicineTokyo Medical and Dental UniversityTokyoJapan
  7. 7.Department of Internal MedicineKosei Chuo General HospitalTokyoJapan
  8. 8.Second Department of Internal MedicineKyorin UniversityTokyoJapan
  9. 9.First Department of Internal MedicineTokyo Medical CollegeTokyoJapan

Personalised recommendations